NIA Interventions Testing Program (ITP)
Government
About
The Interventions Testing Program is an NIA-funded, peer-reviewed programme that tests whether agents fed in the diet extend lifespan and healthspan in genetically heterogeneous UM-HET3 mice. Identical protocols run in parallel at three sites, the Jackson Laboratory, the University of Michigan and UT Health Science Center at San Antonio, with a Data Coordinating Center at the Jackson Laboratory since 2019. Outside investigators propose compounds each year; up to six are accepted, and studies are powered to detect a 10% lifespan increase in either sex, pooled across sites. All results, positive or negative, are submitted for publication. NIA lists 15 agents and 2 combinations that significantly increased median lifespan, including rapamycin, acarbose, 17α-estradiol, canagliflozin, aspirin, NDGA, glycine, captopril and astaxanthin, several with effects confined to or larger in males. A biospecimen repository shares tissues from treated mice.
Rating breakdown
Aggregate 52/100 · rank #16 in the academic & non-profit table full ratings →
Expand a signal to see what contributes to it.
Publications64
- Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice (Strong et al., Aging Cell) ↗
- Rapamycin fed late in life extends lifespan in genetically heterogeneous mice (Harrison et al., Nature) ↗
- Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males (Harrison et al., Aging Cell; online 2013) ↗
- Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α-glucosidase inhibitor or a Nrf2-inducer (Strong et al., Aging Cell) ↗
- Glycine supplementation extends lifespan of male and female mice (Miller et al., Aging Cell) ↗
Discovery39
Trials from ClinicalTrials.gov (this org as lead sponsor), matched to aging by their condition or intervention.
Fundraising92
Grants of the organisation's listed people, name-matched via NIH RePORTER ↗.
- Richard Miller: Common Mechanisms linking Pre- and Post-Natal Exposures for Child Health Outcomes · USD 2M · NIH Office of the Director 5UH3OD023349-11
- Richard Miller: Quantification of Focused Ultrasound-Mediated Macromolecular Delivery to Brain Tumors with MRI · USD 404K · National Cancer Institute 1R21CA297838-01A1
Education5
- Richard Miller ARDD speaker source ↗
Key outputs
- publication Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice (Strong et al., Aging Cell) ↗ 2008
- publication Rapamycin fed late in life extends lifespan in genetically heterogeneous mice (Harrison et al., Nature) ↗ 2009
- publication Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males (Harrison et al., Aging Cell; online 2013) ↗ 2014
- publication Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α-glucosidase inhibitor or a Nrf2-inducer (Strong et al., Aging Cell) ↗ 2016
- publication Glycine supplementation extends lifespan of male and female mice (Miller et al., Aging Cell) ↗ 2019
- publication Acarbose improves health and lifespan in aging HET3 mice (Harrison et al., Aging Cell) ↗ 2019
- publication Canagliflozin extends life span in genetically heterogeneous male but not female mice (Miller et al., JCI Insight) ↗ 2020
- publication Lifespan benefits for the combination of rapamycin plus acarbose and for captopril in genetically heterogeneous mice (Strong et al., Aging Cell) ↗ 2022
- publication Astaxanthin and meclizine extend lifespan in UM-HET3 male mice; several other agents do not (Harrison et al., GeroScience) ↗ 2023
- dataset or tool NIA Interventions Testing Program public data portal on the Mouse Phenome Database (UM-HET3 lifespan outcomes across the three sites, 2004-present) ↗ 2019
Registered clinical trials
5 trials list this organisation as lead sponsor ClinicalTrials.gov ↗
- EFFECTS OF A YERBA MATE EXTRACT IN REDUCING METABOLIC SYNDROME IN OVERWEIGHT INDIVIDUALS ↗ NA · ENROLLING_BY_INVITATION · 2025-10-06
- Evaluation of the Use of Thrombopoietin Receptor Agonists in Adults With Primary ITP in Europe ↗ COMPLETED · 2022-11-24
- ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP ↗ COMPLETED · 2013-08
- Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura ↗ NA · COMPLETED · 2004-10
- Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP) ↗ PHASE1, PHASE2 · COMPLETED · 2003-05
Investment & funding
| Date | Type | Amount | Detail | Counterparties |
|---|---|---|---|---|
| 2026 | grant | USD 2M | National Institute on Aging publicly disclosed FY 2026 award for U01AG022303 'Interventions Testing Program at UM' (University of Michigan site) | National Institute on Aging, University of Michigan |
| 2026 | grant | USD 2M | National Institute on Aging publicly disclosed FY 2026 award for U01AG022308 'Interventions That Retard Mammalian Aging' (Jackson Laboratory site) | National Institute on Aging, Jackson Laboratory |
| 2026 | grant | USD 2M | National Institute on Aging publicly disclosed FY 2026 award for U01AG022307 'Center for Testing Potential Anti-Aging Interventions' (UT Health San Antonio site) | National Institute on Aging, University of Texas Health Science Center at San Antonio |
| 2026 | grant | USD 354K | National Institute on Aging publicly disclosed FY 2026 award for U24AG066346 ITP Data Coordinating Center (Mouse Phenome Database, Jackson Laboratory) | National Institute on Aging, Jackson Laboratory |
Key people
Richard MillerITP principal investigator, University of Michigan site (Professor of Pathology, University of Michigan)Ron KorstanjeITP principal investigator, Jackson Laboratory siteRandy StrongITP principal investigator, UT Health San Antonio siteAdam SalmonITP principal investigator, UT Health San Antonio siteElissa CheslerPrincipal investigator, ITP Data Coordinating Center (Jackson Laboratory)Tiziana CogliatiNIA program officer for the ITPChristy CarterNIA scientific officer for the ITPDavid E. HarrisonITP principal investigator, Jackson Laboratory site (original/long-standing JAX PI; first author of the 2009 rapamycin study)Nadia A. RosenthalITP principal investigator, Jackson Laboratory siteMolly A. BogueContact principal investigator, ITP Data Coordinating Center / Mouse Phenome Database (Jackson Laboratory)
Research fields
Links
Sources
- https://www.nia.nih.gov/research/dab/interventions-testing-program-itp
- https://www.nia.nih.gov/research/dab/interventions-testing-program-itp/about-itp
- https://www.nia.nih.gov/research/dab/interventions-testing-program-itp/publications
- https://medschool.umich.edu/profile/1886/richard-miller
- https://reporter.nih.gov/project-details/11370117
- https://reporter.nih.gov/project-details/11362050
- https://reporter.nih.gov/project-details/11362309
- https://reporter.nih.gov/project-details/11364967
- https://doi.org/10.1038/nature08221
- https://doi.org/10.1111/acel.12170
- https://doi.org/10.1111/j.1474-9726.2008.00414.x
- https://doi.org/10.1111/acel.12496
- https://phenome.jax.org/projects/ITP1
- https://grantome.com/grant/NIH/U24-AG066346
- https://doi.org/10.1111/acel.12953
- https://doi.org/10.1111/acel.12898
- https://doi.org/10.1172/jci.insight.140019
- https://doi.org/10.1111/acel.13724
- https://doi.org/10.1007/s11357-023-01011-0